Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/165870
COMPARTIR / EXPORTAR:
logo share SHARE BASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE

Invitar a revisión por pares abierta
Campo DC Valor Lengua/Idioma
dc.contributor.authorBermúdez-Silva, Francisco Javieres_ES
dc.contributor.authorEspinosa-Jímenez, Vanesaes_ES
dc.contributor.authorCobo-Vuilleumier, Nadiaes_ES
dc.contributor.authorGauthier, Benoit R.es_ES
dc.contributor.authorRojo-Martínez, Gemmaes_ES
dc.contributor.authorTinahones, Francisco J.es_ES
dc.contributor.authorRomero-Zerbo, Silvana Y.es_ES
dc.date.accessioned2018-06-07T11:15:19Z-
dc.date.available2018-06-07T11:15:19Z-
dc.date.issued2016-
dc.identifier.citationXXVIII Congreso Nacional de la Sociedad Española de Diabetes (2016)es_ES
dc.identifier.urihttp://hdl.handle.net/10261/165870-
dc.descriptionResumen del póster presentado al XXVIII Congreso Nacional de la Sociedad Española de diabetes, celebrado en Bilbao del 20 al 22 de abril de 2016.es_ES
dc.description.abstract[Introduction and objectives]: Novel treatments to fight against type 2 diabetes (T2D) are needed. In this context, recent findings suggest that targeting inflammation is a promising complementary therapy. Indeed, there is evidence suggesting a link between anxiety/depression and obesity/T2D. Abnormal-cannabidiol (Abn-CBD) and LH-21 are synthetic cannabinoids whose pharmacology and effects are still unclear. Abn-CBD seems to activate GPR18 and/or GPR55, whereas LH-21 has been reported to antagonize CB1, though some recent report also suggest GPR55-mediated actions. Interestingly, these GPCRs have been related to inflammatory response and have indeed been found in the CNS. Despite preliminary anti-obesity and anti-hyperglycaemic activity of these drugs, there is a lack of information on the putative modulation of inflammation and anxiety/depression. In order to address these gaps, the effects of chronic administration of Abn-CBD and LH-21 was investigated in diet-induced obese/diabetic mice. [Material and methods]: 10 weeks-old C57Bl/6J mice were fed a high-fat diet (45% kcal content) for 15 weeks. Animals developed an obese/diabetic phenotype with insulin resistance, glucose intolerance, fatty liver, altered inflammatory markers and anxiety. Then, groups of ten mice were daily injected with LH-21 (3 mg/Kg), Abn-CBD (0.05 mg/Kg) or vehicle for two weeks. Food intake and body weight was monitored on a daily basis, glucose handling was assessed by ipGTT and ipITT and finally mice were sacrificed for tissue collection. Several adipokines were determined by ELISA, and inflammatory citokines were assessed by V-PLEX proinflammatory panel kit. Liver histopathology was studied by oil-red staining and F4/80 immunohistochemistry. Behavioural performance was evaluated by the open field test and the elevated plus maze, before and after treatment. [Results]: Abn-CBD and LH-21 treatment did not alter food intake and body weight gain, with little impact on glucose handling. However, both drugs showed anti-inflammatory effects to varying degrees. While Abn-CBD decreased the pro-inflammatory markers IL-6, IL-5 and KC-GRO with no changes in other inflammatory markers, such as IL-2, IL-12p70, IFN-γ, IL-10 and adiponectin, LH-21 decreased plasma levels of leptin without altering any other inflammatory marker. Abn-CBD and LH-21 did not decrease fat content in the liver, nevertheless both drugs decreased macrophages infiltrate in this tissue, suggesting an intra-hepatic anti-inflammatory effect. Regarding behavioural performance, Abn-CBD did not affect locomotion or anxiety. By contrast, LH-21 promoted an anxiolytic behaviour by increasing number of entries into open arms and reverting the obesity/diabetes-induced decrease in time spent and distance travelled in open arms of plus maze, without affecting locomotion. [Conclusions]: Abn-CBD and LH-21 ameliorate the inflammatory status in an animal model of type 2 diabetes, the latter indeed reverting obesity/diabetes-induced anxiety.es_ES
dc.description.sponsorshipFunded by the ISCIII (PI13/00309 to FJBS) and the Consejería de Salud de la Junta de Andalucía (PI-0574-2012 to SYRZ).es_ES
dc.language.isoenges_ES
dc.rightsclosedAccesses_ES
dc.titleThe synthetic cannabinoids Abn-CBD and LH-21 ameliorate inflammatory status and anxiety in diet-induced diabetic micees_ES
dc.typepóster de congresoes_ES
dc.description.peerreviewedPeer reviewedes_ES
dc.contributor.funderInstituto de Salud Carlos IIIes_ES
dc.contributor.funderJunta de Andalucíaes_ES
dc.relation.csices_ES
oprm.item.hasRevisionno ko 0 false*
dc.identifier.funderhttp://dx.doi.org/10.13039/501100004587es_ES
dc.identifier.funderhttp://dx.doi.org/10.13039/501100011011es_ES
dc.type.coarhttp://purl.org/coar/resource_type/c_6670es_ES
item.openairetypepóster de congreso-
item.cerifentitytypePublications-
item.languageiso639-1en-
item.grantfulltextnone-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.fulltextNo Fulltext-
Aparece en las colecciones: (CABIMER) Comunicaciones congresos
Ficheros en este ítem:
Fichero Descripción Tamaño Formato
accesoRestringido.pdf15,38 kBAdobe PDFVista previa
Visualizar/Abrir
Show simple item record

CORE Recommender

Page view(s)

313
checked on 29-mar-2024

Download(s)

39
checked on 29-mar-2024

Google ScholarTM

Check


NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.